Skip to main content
. Author manuscript; available in PMC: 2011 May 3.
Published in final edited form as: Biochem Biophys Res Commun. 2005 Mar 4;328(1):43–48. doi: 10.1016/j.bbrc.2004.12.142

Fig. 1.

Fig. 1

Knock down of BRCA2 mRNA (A) and protein (B) in HMEC cells by siRNA (BR2). Total RNA was isolated from control scrambled siRNA (Con)-treated or BRCA2 siRNA (BR2, KD)-treated cells and analyzed by RT-PCR analysis. β-actin was used as a loading control. Similarly, BRCA2 and actin protein levels in the total cell extract were analyzed by Western blot analysis. BRCA2 monoclonal antibody and anti-actin antibody were used for this purpose. Similar results were obtained using anti-BRCA2 phosphorothioate gapmer oligos or when cells were transiently transfected with pSUPER construct expressing BR2 shRNA from H1 RNA gene promoter in HMEC and BT549 cells.